Stoke Therapeutics, Inc. (STOK) Reports Q4 Loss, Tops Revenue Estimates

Stoke Therapeutics, Inc. (STOK) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of$ 0.51. This compares to loss of $0.60 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 64.71%. A quarter ago, it was expected that this company would post a loss of$ 0.52 per share when it actually produced a loss of $0.47, delivering a surprise of 9.62%.Over the last four quarters, the company has ...